Vaccines as an Effective Treatment for Triple-Negative Breast Cancer

Mohan Gao

doi:10.54254/2753-8818/2025.LD25945

Theoretical and Natural ScienceOpen access

Vaccines as an Effective Treatment for Triple-Negative Breast Cancer

Research Article

Open Access

Vaccines as an Effective Treatment for Triple-Negative Breast Cancer

Mohan Gao ^1*

¹ Beijing New Talent Academy

^*Corresponding author: 16601230188@163.com

Published on 13 August 2025

TNS Vol.122

ISSN (Print): 2753-8826

ISSN (Online): 2753-8818

ISBN (Print): 978-1-80590-269-0

ISBN (Online): 978-1-80590-270-6

Download Cover

Abstract

Breast cancer is a malignant tumor that originates from the breast tissue. Triple-negative breast cancer (TNBC) accounts for a certain proportion of all types of breast cancer, and it is a type of breast cancer that is difficult to treat and highly dangerous. Triple-negative breast cancer (TNBC) lacks three receptors, which leads to its difficulty in treatment. The common treatment methods for triple-negative breast cancer (TNBC) mainly include chemotherapy and immunotherapy. Immunotherapy is a treatment approach that targets the tumor's ability to evade the immune system's attack, helping T cells maintain normal activity and stimulating the immune response. Although chemotherapy leads to a relatively good prognosis, it poses significant harm to the human body. In recent years, there have been many advancements in the use of vaccines for treating triple-negative breast cancer (TNBC). This review article will mainly discuss the current progress, advantages, and challenges of using vaccines to treat triple-negative breast cancer (TNBC).

Keywords:

vaccine, triple negative breast cancer, immune response, antibody

View PDF

References

[1]. Lei, S., Zheng, R., Zhang, S., Wang, S., Chen, R., Sun, K., Zeng, H., Zhou, J. and Wei, W. (2021) Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Communications, 41, 1183–1194.

[2]. Livasy, C.A. (2009) Triple-negative breast cancer. Surgical Pathology Clinics, 2, 247-261.

[3]. Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., Diéras, V., Hegg, R., Im, S.A., Shaw Wright, G., Henschel, V., Molinero, L., Chui, S.Y., Funke, R., Husain, A., Winer, E.P., Loi, S. and Emens, L.A. (2018) IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England Journal of Medicine, 379, 2108-2121.

[4]. Medina, M.A., Oza, G., Sharma, A., Arriaga, L.G., Hernández Hernández, J.M., Rotello, V.M. and Ramirez, J.T. (2020) Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. International Journal of Environmental Research and Public Health, 17, 2078.

[5]. Mahfoudh, W., Bettaieb, I., Ghedira, R., Snoussi, K., Bouzid, N., Klayech, Z., Gabbouj, S., Remadi, Y., Hassen, E., Bouaouina, N. and Zakhama, A. (2019) Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia. Journal of Translational Medicine, 17, 123.

[6]. Morse, M.A., Gwin, W.R. ranked 3rd. and Mitchell, D.A. (2021) Cancer Vaccine Therapy: Past and Present. OncoTargets and Therapy, 16, 121-152.

[7]. Fines, C., McCarthy, H. and Buckley, N. (2025) The search for a TNBC vaccine: the guardian vaccine. Cancer Biology & Therapy, 26, 2472432.

[8]. Gilmore, E., McCabe, N., Kennedy, R.D. and Parkes, E.E. (2019) DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. Journal of Oncology, 2019, 4325105.

[9]. Rosa, M.L., Reinert, T., Pauletto, M.M., Sartori, G., Graudenz, M. and Barrios, C.H. (2023) Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives. Translational Breast Cancer Research, 5, 4.

[10]. Korde, L.A., Somerfield, M.R., Carey, L.A., Crews, J.R., Denduluri, N., Hwang, E.S., Khan, S.A., Loibl, S., Morris, E.A., Perez, A., Regan, M.M., Spears, P.A., Sudheendra, P.K., Symmans, W.F., Yung, R.L., Harvey, B.E. and Hershman, D.L. (2021) Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology, 39, 1485-1505.

[11]. Huang, L., Lang, G.T., Liu, Q., Shi, J.X., Shao, Z.M. and Cao, A.Y. (2021) A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes. Annals of Translational Medicine, 9, 301.

[12]. Cortes, J., Haiderali, A., Huang, M., Pan, W., Schmid, P., Akers, K.G., Park, J.E., Frederickson, A.M., Fasching, P.A. and O'Shaughnessy, J. (2023) Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis. BioMed Central Cancer, 23, 792.

[13]. Palma, M. (2025) Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges. Vaccines, 13, 344.

[14]. Poodineh, J., Sirati-Sabet, M., Rajabibazl, M. and Mohammadi-Yeganeh, S. (2020) MiR-130a-3p blocks Wnt signaling cascade in the triple-negative breast cancer by targeting the key players at multiple points. Heliyon, 6, e05434.

[15]. Kaczmarek, M., Poznańska, J., Fechner, F., Michalska, N., Paszkowska, S., Napierała, A. and Mackiewicz, A. (2023) Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. Cells, 12, 2159.

References

[2]. Livasy, C.A. (2009) Triple-negative breast cancer. Surgical Pathology Clinics, 2, 247-261.

[6]. Morse, M.A., Gwin, W.R. ranked 3rd. and Mitchell, D.A. (2021) Cancer Vaccine Therapy: Past and Present. OncoTargets and Therapy, 16, 121-152.

[7]. Fines, C., McCarthy, H. and Buckley, N. (2025) The search for a TNBC vaccine: the guardian vaccine. Cancer Biology & Therapy, 26, 2472432.

[8]. Gilmore, E., McCabe, N., Kennedy, R.D. and Parkes, E.E. (2019) DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. Journal of Oncology, 2019, 4325105.

[13]. Palma, M. (2025) Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges. Vaccines, 13, 344.

Cite this article

Gao,M. (2025). Vaccines as an Effective Treatment for Triple-Negative Breast Cancer. Theoretical and Natural Science,122,1-5.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

About volume

Volume title: Proceedings of ICBioMed 2025 Symposium: Computational Modelling and Simulation for Biology and Medicine

ISBN: 978-1-80590-269-0(Print) / 978-1-80590-270-6(Online)

Editor: Alan Wang, Roman Bauer

Conference website: https://2025.icbiomed.org/london.html

Conference date: 19 September 2025

Series: Theoretical and Natural Science

Volume number: Vol.122

ISSN: 2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).